Stock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat

Stock Track02-26

Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.

The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.

For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198741282?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198741282","market":"hk","top_or_hot":-1,"title":"Stock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat","media":"Stock Track","content":"<p>Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.</p><p>For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.</p><p>For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"","article_id":"1198741282","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198741282","pubTimestamp":1772111265,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药"},"translate_title":"个股追踪|BioCryst Pharmaceuticals盘前大涨5.30%财报业绩强劲营收超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1},"content_text":"Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198741282","isCrawlerRequest":true}